SAB Biotherapeutics (SABS) Change in Receivables (2021 - 2023)

SAB Biotherapeutics has reported Change in Receivables for 3 years, with the latest figure at -$361735.0 in Q3 2023.

• For the quarter ending Q3 2023, Change in Receivables fell 110.86% year-over-year to -$361735.0; the trailing twelve-month figure through Dec 2023 stood at -$5.6 million (down 126.42% YoY), and the FY2023 full-year result was -$5.6 million, down 126.42% from the prior year.
• Change in Receivables for Q3 2023 stood at -$361735.0, up from -$401388.0 in the prior quarter.
• The five-year high for Change in Receivables was $5.5 million in Q2 2021, with the low at -$9.0 million in Q1 2021.
• Historically, Change in Receivables has averaged -$1.9 million across 3 years, with a median of -$2.2 million in 2022.
• The largest YoY upside for Change in Receivables was 148.28% in 2022 against a maximum downside of 235.32% in 2022.
• SAB Biotherapeutics' Change in Receivables stood at -$2.2 million in 2021, then plunged by 235.32% to -$7.4 million in 2022, then surged by 95.1% to -$361735.0 in 2023.
• The last three Change in Receivables figures came in at -$361735.0 (Q3 2023), -$401388.0 (Q2 2023), and -$4.8 million (Q1 2023), per Business Quant data.